Stochholm K, et al. - Published safety data, focusing on mortality, neoplasms, cerebrovascular events and diabetes across a number of large-scale pharmaceutical company growth hormone (GH) registries was assessed in this study. The authors revealed that patients with risk factors for malignancy or type 2 diabetes needed to be treated with caution and monitored during follow-up. However, current published data provided reassurance on the long-term safety profile of GH in patients receiving GH treatment.